Nanotheranostics for Cancer Applications (Record no. 75915)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 05796nam a22006135i 4500 |
001 - CONTROL NUMBER | |
control field | 978-3-030-01775-0 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20220801214048.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 181112s2019 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 9783030017750 |
-- | 978-3-030-01775-0 |
082 04 - CLASSIFICATION NUMBER | |
Call Number | 610.28 |
245 10 - TITLE STATEMENT | |
Title | Nanotheranostics for Cancer Applications |
250 ## - EDITION STATEMENT | |
Edition statement | 1st ed. 2019. |
300 ## - PHYSICAL DESCRIPTION | |
Number of Pages | XIV, 480 p. 89 illus., 83 illus. in color. |
490 1# - SERIES STATEMENT | |
Series statement | Bioanalysis, Advanced Materials, Methods, and Devices, |
505 0# - FORMATTED CONTENTS NOTE | |
Remark 2 | About the Editors -- List of Contributors -- Part I Introduction to Cancer and Nanotechnology -- 1 Introduction -- 2 Biological Events and Barriers to Effective Delivery of Cancer Therapeutics -- 3 Cancer Diagnostics and Therapeutics -- 4 Nanomedicine in Cancer -- 5 Theranostics: A Historical Perspective of Cancer Nanotechnology Paving the Way for Simultaneous Use Applications -- Part II Cancer Nanodiagnostics and Nanotherapeutics -- 6 In Vitro Cancer Diagnostics -- 7 Translational Nanodiagnostics for In Vivo Cancer Detection -- 8 Delivery of Cancer Nanotherapeutics -- 9 Oral Nanotherapeutics for Cancer with Innovations in Lipid and Polymeric Nanoformulations -- 10 Topical and Transdermal Nanomedicines for Cancer Therapy -- 11 Cancer Nanotherapeutics Administered by Non-Conventional Routes -- Part III Regulatory Considerations for Nanomaterial Drug Products -- 12 Regulatory Considerations for Cancer Drug Products Containing Nanomaterials -- 13 Perspectives for Characterizing Drug Component of Theranostic Products Containing Nanomaterials -- Part IV Cancer Nanotheranostics -- 14 Engineering Multifunctional Nanomedicine Platforms for Drug Delivery and Imaging -- 15 Image-Guided Drug Delivery -- 16 Nanotheranostics-Based Imaging for Cancer Treatment Monitoring -- 17 Remotely-Triggered Nanotheranostics -- 18 Concluding Remarks and the Future of Nanotheranostics -- Index. |
520 ## - SUMMARY, ETC. | |
Summary, etc | This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics. Provides a comprehensive review of cancer nanotheranostics Represents the first book-length treatment of the topic Presents a full picture of the field, from basic research through clinical implementation Features evidence-based chapters with excellent illustrations and images to guide and assist the reader. |
700 1# - AUTHOR 2 | |
Author 2 | Rai, Prakash. |
700 1# - AUTHOR 2 | |
Author 2 | Morris, Stephanie A. |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | https://doi.org/10.1007/978-3-030-01775-0 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | eBooks |
264 #1 - | |
-- | Cham : |
-- | Springer International Publishing : |
-- | Imprint: Springer, |
-- | 2019. |
336 ## - | |
-- | text |
-- | txt |
-- | rdacontent |
337 ## - | |
-- | computer |
-- | c |
-- | rdamedia |
338 ## - | |
-- | online resource |
-- | cr |
-- | rdacarrier |
347 ## - | |
-- | text file |
-- | |
-- | rda |
650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Biomedical engineering. |
650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Oncology. |
650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Nanochemistry. |
650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Biomaterials. |
650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Pharmaceutical chemistry. |
650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Biophysics. |
650 14 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Biomedical Engineering and Bioengineering. |
650 24 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Oncology. |
650 24 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Nanochemistry. |
650 24 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Biomaterials. |
650 24 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Pharmaceutics. |
650 24 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
-- | Biophysics. |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
-- | 2364-1126 ; |
912 ## - | |
-- | ZDB-2-ENG |
912 ## - | |
-- | ZDB-2-SXE |
No items available.